Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-03-23
2010-11-09
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387200, C530S387900, C530S391100, C424S130100, C424S131100, C424S139100, C424S172100, C424S178100
Reexamination Certificate
active
07829673
ABSTRACT:
Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
REFERENCES:
patent: 2005/0037969 (2005-02-01), Lu et al.
patent: 2005/0266008 (2005-12-01), Graziano et al.
patent: 2006/0019303 (2006-01-01), Castle et al.
patent: WO-89/08114 (1989-09-01), None
patent: WO-92/01049 (1992-01-01), None
patent: WO-94/17184 (1994-08-01), None
patent: WO-96/16990 (1996-06-01), None
patent: WO-98/16245 (1998-04-01), None
patent: WO-98/16254 (1998-04-01), None
patent: WO-98/50435 (1998-11-01), None
patent: WO-99/62526 (1999-12-01), None
patent: WO-00/06194 (2000-02-01), None
patent: WO-00/40265 (2000-07-01), None
patent: WO-02/06347 (2002-01-01), None
patent: WO-02/32288 (2002-04-01), None
patent: WO 2004058288 (2004-07-01), None
patent: WO-2005/042019 (2005-05-01), None
patent: WO-2005/044855 (2005-05-01), None
patent: WO-2005/103083 (2005-11-01), None
patent: WO-2006/088951 (2006-08-01), None
patent: WO-2006/099875 (2006-09-01), None
patent: WO-2006/125640 (2006-11-01), None
Aarhus, Robert et al., “ADP-ribusyl Cyclase and CD38 Catalyze the Synthesis of a Calcium-mobilizing Metabolite from NADP,”The Journal of Biological Chemistry, vol. 270(51):30327-30333(1995).
Antonelli, Alessandro et al., “Human Anti-CD38 Autoantibodies Raise Intracellular Calcium and Stimulate Insulin Release in Human Pancreatic Islets,”Diabetes, vol. 50:985-991 (2001).
Bolognesi, A. et al., “CD38 as a target of IB4 mAb carrying saporin-S6: Design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia,”Journal of Biological Regulators and Homeostatic Agents, vol. 19:145-152 (2005).
de Weers, M. et al., “Humax-CD38, a New Human CD38 Monoclonal Antibody, Effectively Mediates Killing of Multiple Myeloma and Plasma Cell Leukemia Cells,” abstract, submitted for the 16th European Congress of Immunology—ECI2006. Sep. 6-9, 2006—Paris, France.
de Weers, M. et al., “HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells,” Poster presented at the 1st Joint Meeting of European National Societies of Immunology under auspices of EFIS, Sep. 6-9, 2006.
de Weers, Michel, “HuMax-CD38,” Presentation at the Regional Myeloma Group Meeting (2007).
Donovan, K.A. et al., “Binding and internalization of an antibody engineered ant-CD38 single chain variable fragment (scFv) by human myeloma cells,”Blood, vol. 90(10):88A (1997).
Funaro, Ada et al., “Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation,”The Journal of Immunology, vol. 145(8):2390-2396 (1990).
Funaro, Ada et al., “Human CD38: a versatile leukocyte molecule with emerging clinical perspectives,”Fundamental and Clinical Immunology, vol. 3(3):101-113 (1995).
Funaro, Ada et al., “Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids,”International Immunology, vol. 8(11):1643-1650 (1996).
Funaro, Ada et al., “CD38 Functions Are Regulated Through an Internalization Step,”The Journal of Immunology, vol. 160:2238-2247 (1998).
Genmab, “Humax-CD38 Effective in Preclinical Studies,” retrieved online at http://findarticles.com/p/articles/mi—hb5570/is—200512/ai—n24200986 (2005).
Goldmacher, Victor S. et al., “Anti-CD38-Blocked Ricin: An Immunotoxin for the Treatment of Multiple Myeloma,” Blood, vol. 84(9):3017-3025 (1994).
Hara-Yokoyama, Miki et al., “Alteration of enzymatic properties of cell-surface antigen CD38 by agonistic anti-CD38 antibodies that prolong B cell survival and induce activation,” International Immunopharmacology, vol. 8:59-70 (2008).
Howard, Maureen et al., “Formation and Hydrolysis of Cyclic ADP-Ribose Catalyzed by Lymphocyte Antigen CD38,” Science, vol. 262:1056-1059 (1993).
Jackson, David G. et al., “Isolation of a cDNA Encoding the Human CD38 (T10) Molecule, a Cell Surface Glycoprotein with an Unusual Discontinuous Pattern of Expression During Lymphocyte Differentiation,” The Journal of Immunology, vol. 144(7):2811-2815 (1990).
Johnson, Malisha R. et al., “Primary plasma cell leukemia: morphologic immunophenotypic, and cytogenetic featues of 4 cases treated with chemotherapy and stem cell transplantation,” Annals of Diagnostic Pathology, vol. 10:263-268 (2006).
Konopleva, Marina et al., “Ligation of Cell Surface CD38 Protein with Agonistic Monoclonal Antibody Induces a Cell Growth Signal in Myeloid Leukemia Cells,” The Journal of Immunology, vol. 161:4702-4708 (1998).
Konopleva, Marina et al., “CD38 in Hematopoietic Malignancies,” Human CD38 and Related Molecules.Chem Immunol., vol. 75:189-206 (2000).
Malavasi, Fabio et al., “Human CD38: a glycoprotein in search of a function,” Immunology Today, vol. 15(3):95-97 (1994).
Maloney, David G. et al., “Antibody Therapy for Treatment of Multiple Myeloma,” Seminars in Hematology, vol. 36(1 Suppl. 3):30-33 (1999).
Mills, Charity et al., “Characterization of Monoclonal Antibodies that Inhibit CD38 ADP-Ribosyl Cyclase Activity,” Poster with abstract presented at a student conference at the University of Minnesota (2007).
Parren, P.W.H.I. et al., “HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells,” PWHI Conference Proceeding, Presentation for the CD38 meeting in Torino, Jun. 8-10, 2006.
Parren, “HuMax-CD38,” Conference Proceeding, Presentation for the 23rd International Conference on Advances in the Application of Monoclonal Antibodies in Clinical Oncology, Myconos, Greece (2006).
Parren, “HuMax-CD38,” Conference Proceedings, Presentation for the CD38 metting in Torino (2006).
Peipp, M. et al., “Fully Human CD38 Antibodies Efficiently Trigger ADCC and CDC of Multiple Myeloma and Plasma Cell Leukemia Cells,” Conference Proceedings, Poster Presentation at the 2005 Annual Meeting of the American Society of Hematology, Dec. 12, 2005.
Peipp, Matthias et al., AN PREV200600185745, “Fully human CD38 antibodies efficiently trigger ADCC of multiple myeloma cell lines and primary tumor cells,” Blood, vol. 106(11):944A, 47th Annual Meeting of the American-Society-of-Hematology (2005).
Peng, Kah-Whye et al., “Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker,” Blood, vol. 101(7):2557-2562 (2003).
Stevenson, Freda K. et al., “Preliminary Studies for an Immunotherapeutic Approach to the Treatment of Human Myeloma Using Chimeric Anti-CD38 Antibody,” Blood, vol. 77(5):1071-1079 (1991).
Stevenson, George T., “CD38 as a Therapeutic Target,” Mol. Med., vol. 12(11-12):345-346 (2006).
Takasawa, Shin et al., “Synthesis and Hydrolysis of Cyclic ADP-Ribose by Human Leukocyte Antigen CD38 and Inhibition of the Hydrolysis by ATP,” The Journal of Biological Chemistry, vol. 268(35):26052-26054 (1993).
Vooijs, W.C. et al., “Evaluation of CD38 as Target for Immunotherapy in Multiple Myeloma,” Blood, vol. 85(8):2282-2284 (1995).
Yamashita, Y. et al., “A monoclonal antibody against a murine CD38 homologue delivers a signal to B cells for prolongation of survival and protection against apoptosis in vitro: unresponsiveness of X-linked immunodeficient B cells,” Immunology, vol. 85:248-255 (1995).
Zocchi, Elena et al., “A Single Protein Immunologically Identified as CD38 Displays NAD+ Glycohydrolase, ADP-Ribosyl Cyclase and Cyclic ADP-Ribose Hydrolase Activities at the Outer Surface of Human Erythrocytes,” Biochemical and Bioph
De Weers Michel
Graus Yvo
Oprins Judith
Parren Paul
Van De Winkel Jan
DiGiorgio, Esq. Jeanne M.
Genmab A/S
Gussow Anne M.
Lahive & Cockfield LLP
Remillard, Esq. Jane E.
LandOfFree
Antibodies against CD38 for treatment of multiple myeloma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against CD38 for treatment of multiple myeloma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against CD38 for treatment of multiple myeloma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4235566